SCHEMBL4485797

SCHEMBL4485797

COc1cccc(CNS(=O)(=O)c2ccc3c(OC(C)=O)cccc3c2)c1OC

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 4/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2C9 P11712 1/20 0.48
HSD17B10 Q99714 1/20 0.48
KAT6A Q92794 1/20 0.46
LMNA P02545 2/20 0.45
MAPK1 P28482 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
THRB P10828 1/20 0.44
GAA P10253 2/20 0.43
MAPT P10636 1/20 0.43
HTT P42858 1/20 0.42
ATM Q13315 1/20 0.41
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4479458 0.86 CA2 (0.45) POLBMEN1KMT2ACYP1A2CYP2C9
SCHEMBL4471169 0.86 LMNA (0.50) POLBMEN1KMT2ACYP1A2CYP2C9
SCHEMBL4479011 0.86 CASP6 (0.55) POLBMEN1KMT2ACYP1A2CYP2C9
SCHEMBL4492170 0.84 LMNA (0.50) POLBMEN1KMT2ACYP1A2CYP2C9
SCHEMBL4482883 0.82 CYP19A1 (0.53) POLBKMT2ACYP1A2LMNAMAPK1
SCHEMBL4478333 0.81 ALDH1A1 (0.50) MEN1KMT2ACYP1A2CYP2C9MAPK1
SCHEMBL4470491 0.80 MEN1 (0.53) MEN1KMT2AKAT6ALMNAMAPK1
SCHEMBL4483653 0.78 CYP19A1 (0.53) POLBLMNAMAPK1SMN1; SMN2PKM
SCHEMBL4482015 0.78 MEN1 (0.47) MEN1KMT2ALMNASMN1; SMN2NPSR1
SCHEMBL4490023 0.78 CYP19A1 (0.57) POLBMEN1KMT2ACYP1A2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598418-B2 Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-10-06 US claimed
US-20050215645-A1 Amide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2005-09-29 US claimed
US-7598418-B2 Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-10-06 US disclosed
US-20050215645-A1 Amide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215645-A1 Amide derivatives OGG1, HDAC1, BCL2A1 POLB 296/4885MEN1 4507/4885KMT2A 1012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.